EverSource Wealth Advisors’s Verve Therapeutics VERV Stock Holding History

EverSource Wealth Advisors’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$34	–	4488
2025 Q2	$34	Sell	3 -519	-99%	-$2.96K	﹤0.01%	4209
2025 Q1	$2.39K	Buy	522 +430	+467%	+$2.88K	﹤0.01%	2847
2024 Q4	$519	Buy	+92	New	+$519	﹤0.01%	3186
2023 Q4	–	Sell	-79	Closed	-$1.05K	–	2748
2023 Q3	$1.05K	Buy	+79	New	+$1.27K	﹤0.01%	2190

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

EverSource Wealth Advisors's VERV Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 3 shares — an estimated $34 sold.

EverSource Wealth Advisors first reported a position in VERV in Q3 2023 and held it in 4 quarters. The position peaked at $2.39K in Q1 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

EverSource Wealth Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
EverSource Wealth Advisors sold 3 Verve Therapeutics shares in Q3 2025, an estimated $34.
EverSource Wealth Advisors first reported a position in Verve Therapeutics in Q3 2023 and held it in 4 quarters.
EverSource Wealth Advisors's Verve Therapeutics position peaked at $2.39K in Q1 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.